Fig. 9
From: Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
Mosliciguat capacity to decrease maximal hypoxic PAP (mean) (positive treatment effect) and AUC SaO2 (unwanted desaturation effect) based on effects of representative cycles (n = 4 animals); data are mean ± SEM (n = 4). Mosliciguat inhaled (100 µg/kg nominal dose); intravenous 30 and 100 µg/kg. AUC SaO2 area under the SaO2 curve, PAP mean pulmonary arterial pressure, SaO2 arterial oxygen saturation of hemoglobin, SEM standard error of the mean, VQ ventilation/perfusion